Apogee Therapeutics Past Earnings Performance
Past criteria checks 0/6
Apogee Therapeutics's earnings have been declining at an average annual rate of -109.9%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-109.9%
Earnings growth rate
43.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -20.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Nov 14
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Nov 10We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate
Jun 20Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play
Jun 18We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow
Mar 05Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Mar 05We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn
Nov 21Revenue & Expenses Breakdown
How Apogee Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -147 | 42 | 137 |
| 30 Jun 24 | 0 | -118 | 36 | 108 |
| 31 Mar 24 | 0 | -104 | 30 | 89 |
| 31 Dec 23 | 0 | -84 | 25 | 68 |
| 30 Sep 23 | 0 | -70 | 19 | 54 |
| 30 Jun 23 | 0 | -69 | 12 | 47 |
| 31 Mar 23 | 0 | -52 | 7 | 35 |
Quality Earnings: APGE is currently unprofitable.
Growing Profit Margin: APGE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if APGE's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare APGE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APGE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: APGE has a negative Return on Equity (-19.97%), as it is currently unprofitable.